Skin prick testing in patients using beta-blockers: a retrospective analysis

  • Irene N Fung1 and

    Affiliated with

    • Harold L Kim1, 2Email author

      Affiliated with

      Allergy, Asthma & Clinical Immunology20106:2

      DOI: 10.1186/1710-1492-6-2

      Received: 11 December 2009

      Accepted: 20 January 2010

      Published: 20 January 2010

      Abstract

      Rationale

      The use of beta-blockers is a relative contraindication in allergen skin testing yet there is a paucity of literature on adverse events in this circumstance. We examined a population of skin tested patients on beta-blockers to look for any adverse effects.

      Methods

      Charts from 2004-2008 in a single allergy clinic were reviewed for any patients taking a beta-blocker when skin tested. Data was examined for skin test reactivity, type of skin test, concomitant asthma diagnosis, allergens tested, and adverse events.

      Results

      One hundred and ninety-one patients were taking beta-blockers when skin testing occurred. Seventy-two patients had positive skin tests. No tests resulted in an adverse event.

      Conclusions

      This data demonstrates the relative safety of administrating of skin prick tests to patients on beta-blocker treatment. Larger prospective studies are needed to substantiate the findings of this study.

      Introduction

      Beta antagonists, commonly known as beta-blockers, are a commonly prescribed class of medications. Beta-blockers are used in the treatment of congestive heart failure, coronary heart disease, cardiac arrhythmia, hypertension, tremor, glaucoma, and migraine headache. Importantly, beta-blockers significantly reduce both morbidity and mortality rates in congestive heart failure, in acute coronary syndrome, and post myocardial infarction [13]. However, beta-blockade may place atopic subjects at an increased risk of an anaphylactic reaction. Case reports suggest that when systemic allergic reactions occur secondary to immunotherapy, drugs, foods, and insects stings, they may be of greater severity in patients taking beta-blockers [411].

      Due to the potential of beta-blockers to amplify the effects of anaphylaxis, these drugs are relatively contraindicated during allergy skin testing. The American Academy of Allergy Asthma & Immunology (AAAAI) outlines this in its position statement, stating that "Systemic reactions to skin testing are rare. Nevertheless, special precautions, when these are appropriate, should be taken when the patient who needs sensitivity testing for IgE-mediated disease cannot stop treatment with a beta-blocking agent [12]." However, in our literature review on the topic, no case reports or prospective studies report adverse events in patients on beta-blockers who underwent skin testing. This retrospective study investigates whether there is any increased risk of anaphylaxis in patients who were allergy skin tested while they continued on a beta-blocker medication.

      Methods

      Charts of all patients seen at an allergy clinic in Kitchener, Ontario from 2004 and 2008 were searched for any beta-blocker use at the time of their clinic visit. These records were examined to identify if any individuals who were skin tested, while they continued to take beta-blockers, had any reactions to the skin testing. The charts of the patients who were found to be allergic, based on skin testing, were further analysed regarding the medical history, type of beta-blocker taken and skin test findings.

      Results

      One hundred and ninety-one patients were identified to be taking beta-blockers while undergoing skin testing. From the review of their charts, none of these patients experienced any adverse event secondary to skin testing. Specifically, there were no cases of anaphylaxis in these patients. Also, all patients who were taking beta-blockers at the time of the allergy consultation were skin tested.

      Seventy-two patients on beta-blockers had positive results on skin testing, thus demonstrating an IgE-mediated sensitivity. The mean age of these patients was 60 (range 34-89), and 58% of these patients were male. Some other demographic data for the patients with positive skin test results is reported in Table 1. A few patients had more than one primary reason for referral. Spirometry findings and concomitant medications are also presented in the table as these two factors could have affected the severity of an anaphylactic reaction. Fifteen of the 72 allergic patients also had spirometry testing completed because they had some clinical history of respiratory symptoms. Two of the 15 had an obstructive pattern on their spirometry, as indicated by having a FEV1/FVC < 75% predicted. One patient was taking cetirizine and another was taking amitriptyline at the time of skin testing. These medications may have blunted the skin test response. Other common concomitant medications included HMG-CoA reductase inhibitors, diuretics, acetylsalicylic acid, angiotensin converting enzyme inhibitors, and calcium channel blockers.
      Table 1

      Characterization of Atopic Patients Assessed (N = 72)

        

      n (%)

      Reason for referral

        
       

      General allergy assessment

      34 (47)

       

      Environmental allergies

      13 (18)

       

      Rhinitis or sinusitis

      7 (10)

       

      Anaphylactic event

      5 (7)

       

      Rash or urticaria

      5 (7)

       

      Food allergy

      4 (6)

       

      Asthma

      4 (6)

       

      Angioedema

      3 (4)

       

      Cough

      3 (4)

       

      Drug allergy

      2 (3)

      Spirometry performed

       

      15 (21)

       

      FEV1% <80% predicted

      3 (4)

       

      FEV1/FVC % <75% predicted

      2 (13)

      Other medications

        
       

      HMG-CoA reductase inhibitor Iinhibitors inhibitors

      22 (31)

       

      Diuretic

      19 (26)

       

      ASA

      18 (25)

       

      ACEi

      14 (19)

       

      CCB

      10 (14)

       

      Amitriptyline

      1 (1)

       

      Cetirizine

      1 (1)

      ASA - acetyl salicylic acid, ACEi - angiotensin converting enzyme inhibitor, CCB - calcium channel blocker

      The types of beta-blockers taken by the 72 patients with positive skin findings are summarized in table 2. The majority of patients were on oral agents, with atenolol and propanolol being the most commonly used. Two patients were taking ocular topical beta-blocking agents. Table 3 shows the indications for beta-blocker use. A few patients had more than one indication documented in their charts.
      Table 2

      Assessment of beta-blockers used by patients (N = 72)

        

      n (% patients)

      Beta-blocker route

        
       

      Oral

      70 (97)

       

      Ocular

      2 (3)

      Beta-blocker name

        
       

      Atenolol

      42 (58)

       

      Metoprolol

      15 (21)

       

      Nadolol

      4 (6)

       

      Acebutalol

      4 (6)

       

      Propanolol

      2 (3)

       

      Bisprolol

      2 (3)

       

      Timolol

      1 (1)

       

      Labetolol

      1 (1)

      Table 3

      Indications for beta-blocker use (N = 72)

       

      n (%)

      HTN

      49 (68)

      CAD

      17 (24)

      MI

      7 (10)

      Headache

      2 (3)

      Glaucoma

      2 (3)

      Arrhythmia

      2 (3)

      Tremor

      1 (1)

      HTN = hypertension, CAD = coronary artery disease, MI = myocardial infarction

      The allergens the 72 allergic patients tested positive to are listed in table 4. The majority of positive reactions were to environmental aeroallergens and insect venoms, but some patients were found to be allergic to latex, foods and penicillin.
      Table 4

      Positive skin tests (N = 72)

       

      Number positive (%)

      Ragweed

      25 (35)

      Tree

      24 (33)

      Grass

      24 (33)

      Mold

      22 (31)

      Dust mite

      22 (31)

      Cat

      15 (21)

      Yellow jacket*

      15 (21)

      Wasp*

      11 (15)

      Yellow hornet*

      10 (14)

      White faced hornet*

      9 (13)

      Dog

      7 (10)

      Guinea pig

      3 (4)

      Seafood

      3 (4)

      Hamster

      2 (3)

      Fruit

      2 (3)

      Latex

      2 (3)

      Nut

      2 (3)

      Horse

      1 (1)

      Vegetable

      1 (1)

      Penicillin*

      1 (1)

      Honeybee*

      1 (1)

      *Intradermally tested

      Discussion

      Beta-blockers are relatively contraindicated in both skin testing and immunotherapy for three reasons. They may: 1) worsen anaphylaxis severity; 2) make treatment of anaphylaxis more difficult; and 3) increase the incidence of anaphylaxis itself. First, in terms of anaphylaxis severity, beta-blockers can increase synthesis and release of anaphylactic mediators [13, 14], as well as enhance responsiveness of organs to the mediators released [1518]. In atopic subjects, total IgE production may increase. Those with allergic asthma already have excessive alpha-adrenergic reactivity and beta-blockade may further exacerbate this problem. In the treatment of anaphylaxis, beta-blockade has been shown to blunt the effect of epinephrine in animal and human models [1922]. Finally, in case reports of patients with severe anaphylactic reactions, several patients were coincidently on beta-blocker medications [2329].

      While all of the issues above concerning beta-blockers and anaphylaxis are important, we argue that with allergy skin prick testing and intradermal testing with insect venoms and penicillin, the risk of anaphylaxis is so low that testing can be completed safely on most patients taking beta-blockers. Our study failed to show any adverse events in patients undergoing skin testing while taking beta-blockers. Because systemic reactions to skin testing are so uncommon, larger prospective studies comparing patients who are taking and not taking beta-blockers should be performed to prove any risk of beta-blocker use. It is important to note that fatalities from skin testing regardless of beta-blocker use are extremely rare. Through a national questionnaire study with members of the American Academy of Allergy and Immunology, seven fatalities are known: two occurring in 1964, four between 1980-1983, and one in a more recent report surveying the period between 1990-2001 [3032]. None of these patients were known to be using beta-blockers. Furthermore, we could not find any published reports identifying any life-threatening or fatal reactions when patients taking beta-blockers were skin prick tested. In contrast, there are 88 reports from the American Academy of Allergy and Immunology over this time of allergen immunotherapy fatalities, with 3 of these patients taking beta-blockers [3335]. Thus, while there may be an increased risk of anaphylaxis in patients on beta-blockers undergoing immunotherapy, the degree of risk is likely smaller in patients undergoing allergy skin testing. Of course, standard safety measures should still be available in the clinics where skin testing is being performed.

      This study provides information regarding the safety of skin prick testing in patients taking beta-blocker medications. To date, this is the first study known which assesses this issue specifically. Our retrospective study showed no adverse effects of skin testing in 191 patients on beta-blockers. The fact that 72 patients with positive skin tests were able to tolerate the skin testing without any problems suggests skin testing is likely a safe procedure in most patients on beta-blockers. However, large multi-center prospective studies are required to truly measure any increased risk of anaphylaxis of allergy skin testing in patients taking beta-blockers. Until these larger studies are performed, skin testing should still be performed with caution in patients taking beta-blocker medications.

      Declarations

      Acknowledgements

      We wish to acknowledge Dr. David Fischer for his help in reviewing this paper.

      Authors’ Affiliations

      (1)
      McMaster University
      (2)
      University of Western Ontario

      References

      1. Foody JM, Farrell MH, Krumholz HM: Beta-Blocker Therapy In Heart Failure: Scientific Review. JAMA. 2002, 287 (7): 883-889. 10.1001/jama.287.7.883.View ArticlePubMed
      2. Yusef SPRLJCRSP: Beta Blockade During And After Myocardial Infarction: An Overview Of The Randomized Trials. Prog Cardiovasc Dis. 1985, 27 (5): 335-371. 10.1016/S0033-0620(85)80003-7.View Article
      3. Freemantle N, Cleland J, Young P, Mason J, Harrison J: Beta Blockade After Myocardial Infarction: Systematic Review And Meta Regression Analysis. BMJ. 1999, 318 (7200): 1730-1737.PubMed CentralView ArticlePubMed
      4. Momeni M, Brui B, Baele P, Matta A: Anaphylactic Shock In A Beta-Blocked Child: Usefulness Of Isoproterenol. Paediatr Anaesth. 2007, 17 (9): 897-899. 10.1111/j.1460-9592.2007.02276.x.View ArticlePubMed
      5. Jacobs RL, Rake Gw, Fournier Dc, Chilton RJ, Culver WG, Beckmann CH: Potentiated Anaphylaxis In Patients With Drug-Induced Beta-Adrenergic Blockade. J Allergy Clin Immunol. 1981, 68 (2): 125-127. 10.1016/0091-6749(81)90170-6.View ArticlePubMed
      6. Newman BR, Schultz LK: Epinephrine-Resistant Anaphylaxis In A Patient Taking Propranolol Hydrochloride. Ann Allergy. 1981, 47 (1): 35-37.PubMed
      7. Hannaway PJ, Hopper GD: Severe Anaphylaxis And Drug-Induced Beta-Blockade. N Engl J Med. 1983, 308 (25): 1536-PubMed
      8. Awai LE, Mekori YA: Insect Sting Anaphylaxis And Beta-Adrenergic Blockade: A Relative Contraindication. Ann Allergy. 1984, 53 (1): 48-49.PubMed
      9. Ingall M, Goldman G, Page LB: Beta-Blockade In Stinging Insect Anaphylaxis. JAMA. 1984, 251 (11): 1432-10.1001/jama.251.11.1432b.View ArticlePubMed
      10. Berkelman RL, Finton RJ, Elsea WR: Beta-Adrenergic Antagonists And Fatal Anaphylactic Reactions To Oral Penicillin. Ann Intern Med. 1986, 104 (1): 134-View ArticlePubMed
      11. Stark BJ, Sullivan TJ: Biphasic And Protracted Anaphylaxis. J Allergy Clin Immunol. 1986, 78 (1 Pt 1): 76-83. 10.1016/0091-6749(86)90117-X.View ArticlePubMed
      12. American Academy Of Allergy Asthma & Immunology: Academy Position Statement: Adrenergic Blockers, Allergen Immunotherapy And Skin Testing. AAAAI Media Center. 2002, [Cited 8 A.D. Nov 7], [http://​Www.​Aaaai.​Org/​Members/​Academy_​Statements/​Position_​Statements/​Blockers_​Immuno_​Skin.​Asp]
      13. Kaplan AP, Anderson JA, Valentine MD, Lockey RF, Pierson WE, Zweiman B: Beta-Adrenergic Blockers, Immunotherapy, And Skin Testing. American Academy Of Allergy And Immunology. J Allergy Clin Immunol. 1989, 84 (1): 129-130. 10.1016/0091-6749(89)90186-3.View ArticlePubMed
      14. Mjorndal TO, Chesrown SE, Frey MJ, Reed BR, Lazarus SC, Gold WM: Effect Of Beta-Adrenergic Stimulation On Experimental Canine Anaphylaxis In Vivo. J Allergy Clin Immunol. 1983, 71 (1 Pt 1): 62-70. 10.1016/0091-6749(83)90548-1.View ArticlePubMed
      15. Shereff RH, Harwell W, Lieberman P, Rosenberg EW, Robinson H: Effect Of Beta Adrenergic Stimulation And Blockade On Immediate Hypersensitivity Skin Test Reactions. J Allergy Clin Immunol. 1973, 52 (6): 328-333. 10.1016/0091-6749(73)90091-2.View ArticlePubMed
      16. Nisam MR, Zbinden A, Chesrown S, Barnett D, Gold WM: Distribution Of And Pharmacological Release Of Histamine In Canine Lung In Vivo. J Appl Physiol. 1978, 44 (3): 455-463.PubMed
      17. Matsumura Y, Tan EM, Vaughan JH: Hypersensitivity To Histamine And Systemic Anaphylaxis In Mice With Pharmacologic Beta Adrenergic Blockade: Protection By Nucleotides. J Allergy Clin Immunol. 1976, 58 (3): 387-394. 10.1016/0091-6749(76)90119-6.View ArticlePubMed
      18. Matsumura Y, Tan EM, Vaughan JH: Histamine Hypersensitivity In Mice Induced By Bordetella Pertussis Or Pharmacologic Beta Adrenergic Blockade. Effects Of Adrenergic, Cholinergic, And Other Drugs. J Allergy Clin Immunol. 1976, 58 (3): 395-404. 10.1016/0091-6749(76)90120-2.View ArticlePubMed
      19. Kim Y: Interaction Between Beta Blockers And Epinephrine On Hemodynamics Of Spontaneously Hypertensive Rats. Res Commun Chem Pathol Pharmacol. 1993, 80 (1): 3-19.PubMed
      20. Matsumura Y, Tan EM, Vaughan JH: Hypersensitivity To Histamine And Systemic Anaphylaxis In Mice With Pharmacologic Beta Adrenergic Blockade: Protection By Nucleotides. J Allergy Clin Immunol. 1976, 58 (3): 387-394. 10.1016/0091-6749(76)90119-6.View ArticlePubMed
      21. Forfang K, Simonsen S: Effects Of Atenolol And Pindolol On The Hypokalaemic And Cardiovascular Responses To Adrenaline Infusion. Eur J Clin Pharmacol. 1989, 37 (1): 23-27.PubMed
      22. Raptis S, Rosenthal J, Welzel D, Moulopoulos S: Effects Of Cardioselective And Non-Cardioselective Beta-Blockade On Adrenaline-Induced Metabolic And Cardiovascular Responses In Man. Eur J Clin Pharmacol. 1981, 20 (1): 17-22. 10.1007/BF00554661.View ArticlePubMed
      23. Momeni M, Brui B, Baele P, Matta A: Anaphylactic Shock In A Beta-Blocked Child: Usefulness Of Isoproterenol. Paediatr Anaesth. 2007, 17 (9): 897-899. 10.1111/j.1460-9592.2007.02276.x.View ArticlePubMed
      24. Jacobs RL, Rake GW, Fournier DC, Chilton RJ, Culver WG, Beckmann CH: Potentiated Anaphylaxis In Patients With Drug-Induced Beta-Adrenergic Blockade. J Allergy Clin Immunol. 1981, 68 (2): 125-127. 10.1016/0091-6749(81)90170-6.View ArticlePubMed
      25. Newman BR, Schultz LK: Epinephrine-Resistant Anaphylaxis In A Patient Taking Propranolol Hydrochloride. Ann Allergy. 1981, 47 (1): 35-37.PubMed
      26. Hannaway PJ, Hopper GD: Severe Anaphylaxis And Drug-Induced Beta-Blockade. N Engl J Med. 1983, 308 (25): 1536-PubMed
      27. Awai LE, Mekori YA: Insect Sting Anaphylaxis And Beta-Adrenergic Blockade: A Relative Contraindication. Ann Allergy. 1984, 53 (1): 48-49.PubMed
      28. Ingall M, Goldman G, Page LB: Beta-Blockade In Stinging Insect Anaphylaxis. JAMA. 1984, 251 (11): 1432-10.1001/jama.251.11.1432b.View ArticlePubMed
      29. Berkelman RL, Finton RJ, Elsea WR: Beta-Adrenergic Antagonists And Fatal Anaphylactic Reactions To Oral Penicillin. Ann Intern Med. 1986, 104 (1): 134-View ArticlePubMed
      30. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities From Immunotherapy (IT) And Skin Testing (ST). J Allergy Clin Immunol. 1987, 79 (4): 660-677. 10.1016/S0091-6749(87)80164-1.View ArticlePubMed
      31. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA: Survey Of Fatalities From Skin Testing And Immunotherapy 1985-1989. J Allergy Clin Immunol. 1993, 92 (1 Pt 1): 6-15. 10.1016/0091-6749(93)90030-J.View ArticlePubMed
      32. Bernstein DI, Wanner M, Borish L, Liss GM: Twelve-Year Survey Of Fatal Reactions To Allergen Injections And Skin Testing: 1990-2001. J Allergy Clin Immunol. 2004, 113 (6): 1129-1136. 10.1016/j.jaci.2004.02.006.View ArticlePubMed
      33. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities From Immunotherapy (IT) And Skin Testing (ST). J Allergy Clin Immunol. 1987, 79 (4): 660-677. 10.1016/S0091-6749(87)80164-1.View ArticlePubMed
      34. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA: Survey Of Fatalities From Skin Testing And Immunotherapy 1985-1989. J Allergy Clin Immunol. 1993, 92 (1 Pt 1): 6-15. 10.1016/0091-6749(93)90030-J.View ArticlePubMed
      35. Bernstein DI, Wanner M, Borish L, Liss GM: Twelve-Year Survey Of Fatal Reactions To Allergen Injections And Skin Testing: 1990-2001. J Allergy Clin Immunol. 2004, 113 (6): 1129-1136. 10.1016/j.jaci.2004.02.006.View ArticlePubMed

      Copyright

      © Fung and Kim; licensee BioMed Central Ltd. 2010

      This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

      Advertisement